ALKS
Alkermes plc · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum-inputs (vergelijkbare managers): breedte van houders 0.0% · aandelenstroom -13.5% · netto nieuwe posities 0.0% — formule
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q4 2024
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q2 2026 | 121 | +1 | 123.13M | $6.45B | +12 | −10 |
| Q1 2026 | 122 | -3 | 122.08M | $4.29B | +3 | −7 |
| Q4 2025 | 124 | +2 | 142.93M | $4.00B | +3 | — |
| Q3 2025 | 20 | -1 | 95.12M | $2.85B | — | −2 |
| Q2 2025 | 19 | +2 | 84.64M | $2.42B | +2 | — |
| Q1 2025 | 14 | 0 | 39.73M | $1.31B | — | — |
| Q4 2024 | 14 | 0 | 45.20M | $1.30B | — | — |
| Q3 2024 | 13 | +2 | 43.42M | $1.22B | +2 | — |
| Q2 2024 | 11 | — | 42.07M | $1.01B | — | — |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 12.26M | -5.7% | $352.50M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 12.26M | -5.7% | $352.50M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 3 | State Street Global Advisors ✦ (passief) | 8.81M | — | $253.52M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Wellington Management ✦ | 7.01M | -44.6% | $201.68M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 5 | Wellington Management ✦ | 7.01M | -44.6% | $201.68M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 6 | Wellington Management ✦ | 7.01M | -44.6% | $201.68M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 7 | Wellington Management ✦ | 7.01M | -44.6% | $201.68M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 8 | Wellington Management ✦ | 7.01M | -44.6% | $201.68M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 9 | Wellington Management ✦ | 7.01M | -44.6% | $201.68M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 10 | Renaissance Technologies ✦ | 5.48M | +1.1% | $157.57M | 0.2% | ▲ Add | 3 | SEC ↗ |
| 11 | Geode Capital Management ✦ (passief) | 3.82M | -1.4% | $109.85M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 12 | Geode Capital Management ✦ (passief) | 3.82M | -1.4% | $109.85M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 13 | PRIMECAP Management ✦ | 3.10M | -6.1% | $89.03M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 14 | Norges Bank ✦ (passief) | 1.97M | -6.1% | $56.68M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 811.54K | -2.4% | $23.34M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 811.54K | -2.4% | $23.34M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 811.54K | -2.4% | $23.34M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 18 | AQR Capital Management ✦ | 811.54K | -2.4% | $23.34M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 19 | Millennium Management ✦ | 640.51K | -22.3% | $18.42M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 20 | D. E. Shaw & Co. ✦ | 555.93K | 0.0% | $15.99M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 21 | D. E. Shaw & Co. ✦ | 555.93K | 0.0% | $15.99M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 22 | Fisher Asset Management ✦ | 331.36K | +27.1% | $9.53M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 23 | Two Sigma Investments ✦ | 328.52K | -19.0% | $9.45M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 24 | Citadel Advisors ✦ | 53.21K | -35.8% | $1.53M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 25 | Gotham Asset Management ✦ | 30.94K | -73.1% | $889,748 | 0.0% | ▼ Trim | 2 | SEC ↗ |
"Hun gewicht" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die beheerder — de overtuigingsmaatstaf. ✦ = gecureerde beheerder.
Nieuwe kopers
| Geen nieuwe bijgehouden kopers dit kwartaal. |
Verlaten
| Geen bijgehouden uitstappen dit kwartaal. |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 384 houders, 171.47M aandelen, $5.79B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect verder het vaakst bezitten — aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Officer · 6.91K aand · $339,967
Officer · 664 aand · $32,969
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie